CO95 Growing Acceptance of Minimal Residual Disease (MRD) As a Primary Endpoint in Multiple Myeloma (MM) Clinical Trials
Jun 1, 2024, 00:00 AM
10.1016/j.jval.2024.03.183
https://www.valueinhealthjournal.com/article/S1098-3015(24)00298-5/fulltext
Section Title :
Section Order :
11220
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)00298-5&doi=10.1016/j.jval.2024.03.183